Restricted Research - Award List, Note/Discussion Page

Fiscal Year: 2021

8  Texas A&M University-Kingsville  (84302)

Principal Investigator: Galan, J.

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 400,883

Exceeds $250,000 (Is it flagged?): Yes

Start and End Dates: 1/1/21 - 12/31/22

Restricted Research: YES

Academic Discipline: National Natural Toxins Research Center

Department, Center, School, or Institute: Arts & Sciences

Title of Contract, Award, or Gift: Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs

Name of Granting or Contracting Agency/Entity: National Institutes of Health (NIH)
CFDA Link: HHS
93.855

Program Title: none
CFDA Linked: Allergy, Immunology and Transplantation Research

Note:

SAMS 1.1.10 Antivenom (lgG purified from animals hyper immunized with venom) is the only assured therapy for snakebite envenomation. Current antivenoms are manufactured using crude venoms as immunogens without consideration of toxin-diversity, immunogenicity or toxicity. The resulting, nondirected, immunoglobulin response leads to antivenom with severe restricted snake species efficacy and poor venom toxin neutralization. Therefore, treatment requires higher doses to achieve neutralization which can lead to severe unwanted side effects and higher medical cost. The aims of this proposal are to address these deficiencies by replacing crude venom with humanized mAb produced recombinantly, targeting rationally designed, across broadly conserved venom epitopes, found in the catalytic domain of svMP (snake venom metalloproteases) in medically relevant snakes.

Discussion: No discussion notes

 

Close Window